Top

10-31-2018 | Complications | Review | Article

Update on Therapeutic Options in Lipodystrophy

Journal: Current Diabetes Reports

Authors: Baris Akinci, Rasimcan Meral, Elif Arioglu Oral

Abstract

Purpose of Review

The purpose of this review is to summarize the therapeutic approach for lipodystrophy syndromes with conventional treatment options and metreleptin therapy in detail and to point out the current investigational treatments in development.

Recent Findings

The observation of leptin deficiency in patients with lipodystrophy and the potential of leptin replacement to rescue metabolic abnormalities in animal models of lipodystrophy were followed by the first clinical study of leptin therapy in patients with severe lipodystrophy. This and several other long-term studies demonstrated important benefits of recombinant human leptin (metreleptin) to treat metabolic abnormalities of lipodystrophy. These studies ultimately led to the recent FDA approval of metreleptin for the treatment of generalized lipodystrophy and EMA approval for both generalized and partial lipodystrophy. Additional research efforts in progress focus on novel treatment options, predominantly for patients with partial lipodystrophy.

Summary

Current treatment of generalized lipodystrophy includes metreleptin replacement as an adjunct to diet and standard treatment approach for metabolic consequences of lipodystrophy. Beyond metreleptin, a number of different compounds and treatment modalities are being studied for the treatment of partial lipodystrophy.

Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16(2):310–23. https://doi.org/10.4158/EP09154.RA. CrossRefPubMed

Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220–34. https://doi.org/10.1056/NEJMra025261. CrossRefPubMed

Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin N Am. 2004;33(2):305–31. https://doi.org/10.1016/j.ecl.2004.03.003. CrossRef

Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313–25. https://doi.org/10.1210/jc.2011-1159. CrossRefPubMedPubMedCentral

• Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500–11. https://doi.org/10.1210/jc.2016-2466. A multisociety practice guideline summarizing the diagnosis and management of lipodystrophy syndromes. CrossRefPubMedPubMedCentral

Akinci B, Sahinoz M, Oral E. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Lipodystrophy syndromes: presentation and Treatment. South Dartmouth: Endotext; 2000.

Papendieck L, Araujo MB. Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy. J Pediatr Endocrinol Metab. 2018;31(1):77–83. https://doi.org/10.1515/jpem-2017-0355. CrossRefPubMed

Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107–16. CrossRefPubMedPubMedCentral

Akinci G, Topaloglu H, Akinci B, Onay H, Karadeniz C, Ergul Y, et al. Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. Eur J Med Genet. 2016;59(6–7):320–4. https://doi.org/10.1016/j.ejmg.2016.05.001. CrossRefPubMedPubMedCentral

10.

Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9):2623–33. https://doi.org/10.1172/JCI38660. CrossRefPubMedPubMedCentral

11.

Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89(6):2608–15. https://doi.org/10.1210/jc.2004-0433. CrossRefPubMed

12.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, et al. Roux-en-Y gastric bypass Vs. sleeve gastrectomy: balancing the risks of surgery with the benefits of weight loss. Obes Surg. 2017;27(1):154–61. https://doi.org/10.1007/s11695-016-2265-2. CrossRefPubMed

13.

Melvin A, Adams C, Flanagan C, Gaff L, Gratton B, Gribble F, et al. Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1. J Clin Endocrinol Metab. 2017;102(10):3616–20. https://doi.org/10.1210/jc.2017-01235. CrossRefPubMedPubMedCentral

14.

Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care. 2006;29(6):1380–2. https://doi.org/10.2337/dc06-0130. CrossRefPubMed

15.

Ciudin A, Baena-Fustegueras JA, Fort JM, Encabo G, Mesa J, Lecube A. Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass. Clin Endocrinol. 2011;75(3):403–4. https://doi.org/10.1111/j.1365-2265.2011.04057.x. CrossRef

16.

Grundfest-Broniatowski S, Yan J, Kroh M, Kilim H, Stephenson A. Successful treatment of an unusual case of FPLD2: the role of Roux-en-Y gastric bypass-case report and literature review. J Gastrointest Surg. 2017;21(4):739–43. https://doi.org/10.1007/s11605-016-3300-2. CrossRefPubMed

17.

Vantyghem MC, Vigouroux C, Magre J, Desbois-Mouthon C, Pattou F, Fontaine P, et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care. 1999;22(8):1374–6. CrossRefPubMed

18.

Luedtke A, Boschmann M, Colpe C, Engeli S, Adams F, Birkenfeld AL, et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res. 2012;44(4):306–11. https://doi.org/10.1055/s-0031-1301284. CrossRefPubMed

19.

Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33(5):385–9. https://doi.org/10.1016/j.diabet.2007.04.005. CrossRefPubMed

20.

McLaughlin PD, Ryan J, Hodnett PA, O'Halloran D, Maher MM. Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement. AJR Am J Roentgenol. 2012;199(5):W602–6. https://doi.org/10.2214/AJR.11.8110. CrossRefPubMed

21.

•• Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133(4):263–74. This is an open-label prospective study showing the benefits of TZDs in patients with partial lipodystrophy.

22.

Agostini M, Schoenmakers E, Beig J, Fairall L, Szatmari I, Rajanayagam O, et al. A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes. 2018;67(6):1086–92. https://doi.org/10.2337/db17-1236. CrossRefPubMed

23.

Sleilati GG, Leff T, Bonnett JW, Hegele RA. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Endocr Pract. 2007;13(6):656–61. https://doi.org/10.4158/EP.13.6.656. CrossRefPubMed

24.

Iwanishi M, Ebihara K, Kusakabe T, Chen W, Ito J, Masuzaki H, et al. Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. Metabolism. 2009;58(12):1681–7. https://doi.org/10.1016/j.metabol.2009.04.043. CrossRefPubMed

25.

Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240–4. CrossRefPubMed

26.

Banning F, Rottenkolber M, Freibothe I, Seissler J, Lechner A. Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist. Diabet Med. 2017;34(12):1792–4. https://doi.org/10.1111/dme.13527. CrossRefPubMed

27.

Oliveira J, Lau E, Carvalho D, Freitas P. Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J Med Case Rep. 2017;11(1):12. https://doi.org/10.1186/s13256-016-1175-1. CrossRefPubMedPubMedCentral

28.

Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030–40. https://doi.org/10.2337/db16-0733. CrossRefPubMed

29.

Johns KW, Bennett MT, Bondy GP. Are HIV positive patients resistant to statin therapy? Lipids Health Dis. 2007;6:27. https://doi.org/10.1186/1476-511X-6-27. CrossRefPubMedPubMedCentral

30.

Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials. 2008;9(4):254–68. https://doi.org/10.1310/hct0904-254. CrossRefPubMed

31.

•• Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570–8. https://doi.org/10.1056/NEJMoa012437. This is the first clinical study showing dramatic benefits of leptin therapy in patients with lipodystrophy.

32.

Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams-Huet B, Garg A. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013;168(5):771–8. https://doi.org/10.1530/EJE-12-0969. CrossRefPubMedPubMedCentral

33.

Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401(6748):73–6. https://doi.org/10.1038/43448. CrossRefPubMed

34.

Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage DB, Long A, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60(3):479–89. https://doi.org/10.1007/s12020-018-1589-1.

35.

Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, Pazos M, et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine. 2015;49(1):139–47. https://doi.org/10.1007/s12020-014-0450-4.

36.

Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2018;27. https://doi.org/10.1007/s40618-018-0887-z.

37.

Tsoukas MA MC. Endocrinology Adult and Pediatric. In: Jameson JL DL, editor. 7 ed.: Saunders, In Press.

38.

McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004;89(9):4258–63. https://doi.org/10.1210/jc.2003-031868. CrossRefPubMed

39.

Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513–9. CrossRefPubMed

40.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92(2):532–41. https://doi.org/10.1210/jc.2006-1546. CrossRefPubMed

41.

Schlogl H, Muller K, Horstmann A, Miehle K, Puschel J, Villringer A, et al. Leptin substitution in patients with lipodystrophy: neural correlates for long-term success in the normalization of eating behavior. Diabetes. 2016;65(8):2179–86. https://doi.org/10.2337/db15-1550. CrossRefPubMed

42.

Schlogl H, Muller K, Horstmann A, Pleger B, Miehle K, Moller H et al. Leptin-substitution in patients with congenital lipodystrophy increases connectivity in reward-related brain structures: an fMRI study. Exp Clin Endocrinol Diabetes 2014;122(3). doi: https://doi.org/10.1055/s-0034-1371982.

43.

Schlogl H, Muller K, Horstmann A, Miehle K, Pleger B, Moller H, et al. Leptin-substitution increases connectivity in reward-related brain areas in patients with congenital lipodystrophy. Diabetologia. 2015;58:S71–S.

44.

• Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345–50. https://doi.org/10.1172/JCI15001. This study shows the efficacy of leptin treatment to improve insulin-stimulated hepatic and peripheral glucose metabolism in lipodystrophic patients. CrossRefPubMedPubMedCentral

45.

Vatier C, Fetita S, Boudou P, Tchankou C, Deville L, Riveline J, et al. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes Metab. 2016;18(7):693–7. https://doi.org/10.1111/dom.12606. CrossRefPubMed

46.

Muniyappa R, Brown RJ, Mari A, Joseph J, Warren MA, Cochran EK, et al. Effects of leptin replacement therapy on pancreatic beta-cell function in patients with lipodystrophy. Diabetes Care. 2014;37(4):1101–7. https://doi.org/10.2337/dc13-2040. CrossRefPubMedPubMedCentral

47.

• Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802–10. https://doi.org/10.1210/jc.2014-4491. This study defines predictors for treatment response to metreleptin. CrossRefPubMedPubMedCentral

48.

Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922–32. https://doi.org/10.4158/EP11229.OR. CrossRefPubMedPubMedCentral

49.

Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27–35. https://doi.org/10.1007/s00125-009-1502-9. CrossRefPubMed

50.

Vatier C, Arnaud L, Prieur X, Guyomarch B, Le May C, Bigot E, et al. One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes. Diabetes Metab. 2017;43(3):275–9. https://doi.org/10.1016/j.diabet.2016.08.004. CrossRefPubMed

51.

Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J Diabetes Metab 2016;7(3). doi: https://doi.org/10.4172/2155-6156.1000659.

52.

Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785–92. https://doi.org/10.1210/jc.2011-2229. CrossRefPubMed

53.

Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56(4):508–16. https://doi.org/10.1016/j.metabol.2006.11.010. CrossRefPubMedPubMedCentral

54.

Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26(1):30–5. CrossRefPubMed

55.

Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41(4):753–60. https://doi.org/10.1002/hep.20672. CrossRefPubMed

56.

• Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131–7. https://doi.org/10.1016/j.jhep.2013.02.007. The study reports the effect of metreleptin on hepatic disease associated with lipodystrophy. CrossRefPubMed

57.

Machado MV, Cortez-Pinto H. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already? Expert Rev Gastroenterol Hepatol. 2013;7(6):513–5. https://doi.org/10.1586/17474124.2013.814903. CrossRefPubMed

58.

Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, et al. Effects of metreleptin in pediatric patients with lipodystrophy. J Clin Endocrinol Metab. 2017;102(5):1511–9. https://doi.org/10.1210/jc.2016-3628. CrossRefPubMedPubMedCentral

59.

Casey SP, Lokan J, Testro A, Farquharson S, Connelly A, Proietto J, et al. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. Am J Transplant. 2013;13(11):3031–4. https://doi.org/10.1111/ajt.12436. CrossRefPubMed

60.

Friedman J. The long road to leptin. J Clin Invest. 2016;126(12):4727–34. https://doi.org/10.1172/JCI91578. CrossRefPubMedPubMedCentral

61.

• Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, et al. Metreleptin improves insulin sensitivity independent of food intake in humans with lipodystrophy. J Clin Invest. 2018. https://doi.org/10.1172/JCI95476. The study shows that metreleptin improves insulin sensitivity and decreases hepatic and circulating triglycerides independent of its effects on food intake.

62.

Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199–207. https://doi.org/10.1210/jc.2003-032140. CrossRefPubMed

63.

• Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002;87(7):3110–7. https://doi.org/10.1210/jcem.87.7.8591. The study investigates the effect of metreleptin on pituitary hormones in patients with lipodystrophy. CrossRefPubMed

64.

Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255–63. https://doi.org/10.1016/j.metabol.2004.08.021. CrossRefPubMed

65.

Abel BS, Muniyappa R, Stratton P, Skarulis MC, Gorden P, Brown RJ. Effects of recombinant human leptin (metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients. Neuroendocrinology. 2016;103(3–4):402–7. https://doi.org/10.1159/000439432. CrossRefPubMed

66.

Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012;97(2):563–7. https://doi.org/10.1210/jc.2011-1896. CrossRefPubMed

67.

Oral EA, Javor ED, Ding L, Uzel G, Cochran EK, Young JR, et al. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab. 2006;91(2):621–8. https://doi.org/10.1210/jc.2005-1220. CrossRefPubMed

68.

Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin’s vital role in reproduction. Obstet Gynecol. 2012;119(2 Pt 2):452–5. https://doi.org/10.1097/AOG.0b013e31822cecf7. CrossRefPubMedPubMedCentral

69.

Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016;9(1):59–68. https://doi.org/10.1586/17512433.2016.1096772. CrossRefPubMed

70.

Kamran F, Rother KI, Cochran E, Safar Zadeh E, Gorden P, Brown RJ. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr. 2012;78(5–6):320–5. https://doi.org/10.1159/000341398. CrossRefPubMed

71.

Lebastchi J, Ajluni N, Neidert A, Oral EA. A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin. J Clin Endocrinol Metab. 2015;100(11):3967–70. https://doi.org/10.1210/jc.2015-2589. CrossRefPubMedPubMedCentral

72.

Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Reynolds JC, et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab. 2014;99(8):E1493–500. https://doi.org/10.1210/jc.2014-1353. CrossRefPubMedPubMedCentral

73.

Simha V, Zerwekh JE, Sakhaee K, Garg A. Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2002;87(11):4942–5. https://doi.org/10.1210/jc.2002-020792. CrossRefPubMed

74.

Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, et al. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol. 2016;85(1):137–49. https://doi.org/10.1111/cen.12980. CrossRef

75.

Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162(6):1083–91. https://doi.org/10.1530/EJE-09-1027. CrossRefPubMed

76.

• Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2016;57(1):45–50. https://doi.org/10.3109/10428194.2015.1040015. This article focuses on lymphoma development in patients with lipodystrophy. CrossRefPubMed

77.

Aslam A, Savage DB, Coulson IH. Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration. Int J Dermatol. 2015;54(7):827–9. https://doi.org/10.1111/ijd.12185. CrossRefPubMed

78.

Bae MJ, Kim SS, Kim WJ, Yi YS, Jeon YK, Kim BH, et al. High prevalence of papillary thyroid cancer in Korean women with insulin resistance. Head Neck. 2016;38(1):66–71. https://doi.org/10.1002/hed.23848. CrossRefPubMed

79.

Pitoia F, Abelleira E, Bueno F, Urciuoli C, Schmidt A, Niepomniszcze H. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine. 2015;48(3):894–901. https://doi.org/10.1007/s12020-014-0416-6. CrossRefPubMed

80.

Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317(3):137–40. https://doi.org/10.1056/NEJM198707163170303. CrossRefPubMed

81.

Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993;42(5):696–705. CrossRefPubMed

82.

Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract. 1995;28(Suppl):S185–94. CrossRefPubMed

83.

Satoh M, Yoshizawa A, Takesue M, Saji T, Yokoya S. Long-term effects of recombinant human insulin-like growth factor I treatment on glucose and lipid metabolism and the growth of a patient with congenital generalized lipodystrophy. Endocr J. 2006;53(5):639–45. CrossRefPubMed

84.

Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2003;2(6):630–5. CrossRefPubMed

85.

Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, Group GHISC. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92(3):902–10. https://doi.org/10.1210/jc.2006-1610. CrossRefPubMed

86.

Bang P, Polak M, Woelfle J, Houchard A, Group EIRS. Effectiveness and safety of rhIGF-1 therapy in children: the European Increlex® Growth Forum Database Experience. Horm Res Paediatr. 2015;83(5):345–57. https://doi.org/10.1159/000371798. CrossRefPubMed

87.

Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36(10):675–87. https://doi.org/10.1016/j.tips.2015.07.001. CrossRefPubMed

88.

Gaudet D, Digenio A, Alexander V, Arca M, Jones A, Stroes E, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (Fcs). Clin Cardiol. 2017;40:14.

89.

Gouni-Berthold I, Alexander V, Digenio A, DuFour R, Steinhagen-Thiessen E, Martin S, et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. Atheroscler Suppl. 2017;28:E1–2. https://doi.org/10.1016/j.atherosclerosissup.2017.08.003. CrossRef

90.

Olkkonen VM, Sinisalo J, Jauhiainen M. New medications targeting triglyceride-rich lipoproteins: can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk? Atherosclerosis. 2018;272:27–32. https://doi.org/10.1016/j.atherosclerosis.2018.03.019. CrossRefPubMed

91.

Stahel P, Xiao C, Hegele RA, Lewis GF. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2017;34:595–604. https://doi.org/10.1016/j.cjca.2017.12.007. CrossRefPubMed

92.

Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–7. https://doi.org/10.1056/NEJMc1705994. CrossRefPubMed

93.

Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 1998;39(1):17–30. PubMed

94.

Srivastava RAK, Cornicelli JA, Markham B, Bisgaier CL. Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-delta-mediated transcriptional mechanism. Mol Cell Biochem. 2018. https://doi.org/10.1007/s11010-018-3353-5.

95.

Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016;10(5):1212–22. https://doi.org/10.1016/j.jacl.2016.08.002. CrossRefPubMed

96.

Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003;92(5):538–43. CrossRefPubMed

97.

Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697–704. https://doi.org/10.1007/s40265-017-0723-3. CrossRefPubMed

98.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–52. https://doi.org/10.1172/JCI98814. CrossRefPubMedPubMedCentral

99.

Abulizi A, Perry RJ, Camporez JPG, Jurczak MJ, Petersen KF, Aspichueta P, et al. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J. 2017;31(7):2916–24. https://doi.org/10.1096/fj.201700001R. CrossRefPubMedPubMedCentral

100.

Baptista LS, da Silva KR, da Pedrosa CS, Claudio-da-Silva C, Carneiro JR, Aniceto M, et al. Adipose tissue of control and ex-obese patients exhibit differences in blood vessel content and resident mesenchymal stem cell population. Obes Surg. 2009;19(9):1304–12. https://doi.org/10.1007/s11695-009-9899-2. CrossRefPubMed

101.

Baptista LS, Silva KR, Borojevic R. Obesity and weight loss could alter the properties of adipose stem cells? World J Stem Cells. 2015;7(1):165–73. https://doi.org/10.4252/wjsc.v7.i1.165. CrossRefPubMedPubMedCentral

102.

Matsushita K, Dzau VJ. Mesenchymal stem cells in obesity: insights for translational applications. Lab Investig. 2017;97(10):1158–66. https://doi.org/10.1038/labinvest.2017.42. CrossRefPubMed

Medicine Matters Diabetes

Update on Therapeutic Options in Lipodystrophy

Abstract

Purpose of Review

Recent Findings

Summary

New additions to the Adis Journal Club

ADA 2022 coverage